Bayliss M K, Frick L W
Biomet Division, Glaxo Wellcome R&D, Hertfordshire, SG12 0DP, UK.
Curr Opin Drug Discov Devel. 1999 Jan;2(1):20-5.
The profound technological advances that are now occurring early in the drug discovery process have enabled lead identification groups to deliver very large numbers of promising compounds to the project teams responsible for lead optimization and candidate selection. This success has applied significant pressure to the 'traditional' selection processes performed during the preclinical optimization stages of a new medicine, where compounds with the optimal balance of potency, selectivity, safety and pharmacokinetics, are identified for progression using an iterative synthesis and testing process. Thus, the need exists for higher-throughput methods of determining pharmacokinetic parameters to enable rational decisions to be made on large numbers of compounds. Protocols detailing the administration of mixtures of compounds, cassette dosing, to single animals have been used successfully to increase throughput, and, at the same time address ethical considerations by reducing animal usage. Typically, cassettes of up to ten compounds have been administered in one dose via the intravenous or oral routes. The samples produced have then been analyzed by mass spectrometry.
目前在药物发现过程早期出现的深刻技术进步,使先导化合物识别团队能够向负责先导化合物优化和候选药物选择的项目团队提供大量有前景的化合物。这一成功给新药临床前优化阶段所采用的“传统”选择过程带来了巨大压力,在这个阶段,要通过反复的合成和测试过程,识别出在效力、选择性、安全性和药代动力学方面达到最佳平衡的化合物,以便推进研究。因此,需要有更高通量的方法来测定药代动力学参数,从而能够对大量化合物做出合理决策。详细说明将化合物混合物给药(即“分组给药”)至单只动物的方案已成功用于提高通量,同时通过减少动物使用量来解决伦理问题。通常,一次通过静脉或口服途径给予多达十种化合物的分组。然后对产生的样本进行质谱分析。